<DOC>
	<DOCNO>NCT00723918</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness methadone alone combination SAB378 treatment painful HIV-associated neuropathy .</brief_summary>
	<brief_title>Combination Investigational Cannabinoid Methadone HIV-associated Neuropathy</brief_title>
	<detailed_description>Distal sensory polyneuropathy common neurological complication HIV disease treatment . To date standard effective therapy identify . In study , scientist evaluate effectiveness treat HIV-associated neuropathy methadone alone combination novel cannabinoid SAB378 . A cannabinoid molecule find Cannabis plant . Cannabis cannabinoids effective analgesic pain reliever . The rationale combination therapy twofold : ( 1 ) medication unique mechanism action may affect different aspect neuropathic pain ( 2 ) combination therapy may act synergistically—meaning combined effect may great effect drug alone . Approximately 84 participant enrol double-blind , placebo-controlled , crossover study . Participants randomly assign three treatment groups—those receive methadone SAB378 placebo ( inactive substance ) , receive methadone active SAB378 , receive methadone placebo SAB378 placebo . All participant expose 3 treatment group study . This trial part Neurologic AIDS Research Consortium , effective collaborative clinical study group dedicate study HIV-associated neurological disease .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>HIV1 infection HIVassociated neuropathy diagnose neurologist Presence least moderate pain score basis completion baseline pain diary Stable antiretroviral regimen least 8 week prior study entry . Hemoglobin ≥ 8.0 g/dL male ≥ 7.5 g/dL female Active AIDSdefining opportunistic infection within 45 day prior study entry Renal insufficiency Chronic liver disease B12 deficiency Family history hereditary neuropathy Discontinuation dideoxynucleoside NRTI within 16 week prior entry On neuroregenerative therapy Treatment neurotoxic drug within 120 day prior entry Respiratory compromise Hypotension Active substance abuse dependence History alcoholrelated complication within 6 month prior screen Women childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>HIV-associated neuropathy</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>cannabinoid</keyword>
	<keyword>Cannabis</keyword>
	<keyword>methadone</keyword>
	<keyword>distal sensory polyneuropathy</keyword>
	<keyword>polyneuropathy</keyword>
</DOC>